Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Combining genetics and MRD assessment identifies adult Ph- ALL patients who benefit from allo-HSCT, with a 3-year OS of up to 81% in low-risk groups.

• Why it matters: Accurate risk stratification in adult Philadelphia chromosome-negative ALL is essential for optimizing therapy, but current methods lack consistency and centralized evaluation, risking suboptimal treatment decisions.
• What they did: The study analyzed 436 adults using centralized genetic and MRD assessments, classifying patients into high or low genetic risk and MRD status, then evaluating their outcomes with or without allo-HSCT.
• The result: Patients with favorable genetics and low MRD had an 81% 3-year OS, enabling precise identification of candidates for less intensive therapy, while high-risk patients benefited from allo-HSCT, improving survival prospects.